2-(p-methoxyphenyl)-2-phenylethylamine | 51431-54-0

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 2-(p-methoxyphenyl)-2-phenylethylamine
• 英文别名: 2-(4-Methoxyphenyl)-2-phenylethanamine
• CAS: 51431-54-0
• 化学式: C₁₅H₁₇NO
• 分子量: 227.306
• InChiKey: RZIUXULLPNOGIY-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.7
• 重原子数：
  17
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.2
• 拓扑面积：
  35.2
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  2-(p-methoxyphenyl)-2-phenylethylamine 在 氢碘酸 作用下， 以 溶剂黄146 为溶剂， 生成 (+/-)-2-(p-Hydroxy-phenyl)-2-phenyl-ethylamin
  参考文献：
  名称：

  取代的2,2-二苯乙胺的合成及其肾上腺皮质激素抑制活性。

  摘要：

  DOI：

  10.1021/jm00301a003
• 作为产物：
  描述：

  (4-methoxy-benzhydryl)-malonic acid diethyl ester 在 氢氧化钾 作用下， 以 乙醇 为溶剂， 生成 2-(p-methoxyphenyl)-2-phenylethylamine
  参考文献：
  名称：

  取代的2,2-二苯乙胺的合成及其肾上腺皮质激素抑制活性。

  摘要：

  DOI：

  10.1021/jm00301a003

文献信息

• ORGANIC COMPOUNDS
  申请人：Breitenstein Werner

  公开号：US20090233920A1

  公开（公告）日：2009-09-17

  The invention relates to 3,5-substituted piperidine compounds, these compounds for use in the diagnostic and therapeutic treatment of a warm-blooded animal, especially for the treatment of a disease (=disorder) that depends on activity of renin; the use of a compound of that class for the preparation of a pharmaceutical formulation for the treatment of a disease that depends on activity of renin; the use of a compound of that class in the treatment of a disease that depends on activity of renin; pharmaceutical formulations comprising a 3,5-substituted piperidine compound, and/or a method of treatment comprising administering a 3,5-substituted piperidine compound, a method for the manufacture of a 3,5-substituted piperidine compound, and novel intermediates and partial steps for its synthesis. The preferred compounds (which can also be present as salts) have the formula I wherein R1, R2, T, R3 and R4 are as defined in the specification.

  该发明涉及3,5-取代哌啶化合物，这些化合物用于诊断和治疗温血动物，特别是用于治疗依赖肾素活性的疾病（=紊乱）；该类化合物用于制备用于治疗依赖肾素活性疾病的药物配方；该类化合物用于治疗依赖肾素活性的疾病；包括3,5-取代哌啶化合物的药物配方，和/或包括给予3,5-取代哌啶化合物的治疗方法，一种用于制造3,5-取代哌啶化合物的方法，以及其合成的新中间体和部分步骤。优选的化合物（也可以存在为盐）具有式I的结构，其中R1、R2、T、R3和R4如规范中定义。
• Direct Access to Primary Amines from Alkenes by Selective Metal‐Free Hydroamination
  作者：Yi‐Dan Du、Bi‐Hong Chen、Wei Shu

  DOI：10.1002/anie.202016679

  日期：2021.4.26

  selective synthesis of primary amines from easily available precursors is attractive yet challenging. Herein, we report the rapid synthesis of primary amines from alkenes via metal‐free regioselective hydroamination at room temperature. Ammonium carbonate was used as ammonia surrogate for the first time, allowing for efficient conversion of terminal and internal alkenes into linear, α‐branched, and α‐tertiary

  由容易获得的前体直接和选择性合成伯胺是有吸引力的，但仍具有挑战性。在此，我们报道了室温下通过无金属的区域选择性加氢胺从烯烃快速合成伯胺的方法。碳酸铵首次用作氨替代物，可在温和条件下将末端和内部烯烃有效转化为线性，α支化和α叔伯胺。该方法提供了一种直接而有效的方法，可用于制药化学和其他领域特别感兴趣的各种先进的，高度官能化的伯胺。
• THIAZOLYL COMPOUNDS USEFUL AS KINASE INHIBITORS
  申请人：Marinier Anne

  公开号：US20100048581A1

  公开（公告）日：2010-02-25

  The invention provides compounds of formula I [INSERT CHEMICAL STRUCTURE HERE] (I) and pharmaceutically acceptable salts thereof. The formula I thiazolyl compounds inhibit tyrosine kinase activity thereby making them useful as anticancer agents and for the treatment of Alzheimer's Disease.

  这项发明提供了化合物I的公式[插入化学结构在这里]（I）及其药学上可接受的盐。公式I的噻唑基化合物抑制酪氨酸激酶活性，因此可用作抗癌剂以及治疗阿尔茨海默病。
• Synthesis of 3-arylindole derivatives from nitroalkane precursors
  作者：Chia-Yu Huang、Chun-Wei Kuo、Ashok Konala、Tang-Hao Yang、Lyu Lin、Yu-Wen Chen、Veerababurao Kavala、Ching-Fa Yao

  DOI：10.1039/c6ra21144e

  日期：——

  3-Arylindole derivatives were synthesized by Cu(I) catalysed intramolecular Ullmann coupling of 2-bromoarylaminoalkanes. 2-Bromoarylaminoalkanes were synthesized from 2-bromoarylnitroalkanes, which in turn prepared through AlCl3-mediated Friedel–Crafts alkylation of bromo-substituted β-nitrostyrenes and arenes.

  通过铜（I）催化的2-溴芳基氨基链烷烃的分子内Ullmann偶联合成了3-芳基吲哚衍生物。2-溴芳基氨基链烷烃是由2-溴芳基硝基链烷烃合成的，而后者又是通过AlCl 3介导的溴代β-硝基苯乙烯和芳烃的Friedel-Crafts烷基化反应制备的。
• IDENTIFICATION OF ANTI-CANCER COMPOUNDS AND COMPOUNDS FOR TREATING HUNTINGTON'S DISEASE AND METHODS OF TREATMENT THEREOF
  申请人：Stockwell Brent R.

  公开号：US20100022637A1

  公开（公告）日：2010-01-28

  Small molecule screening via high-throughput screening (HTS) methods was employed to identify compounds useful for treating or preventing cancer (such as compounds that enable cells to overcome E6-oncoprotein-mediated drug resistance) or neurodegenerative disorders (such as Huntington's disease, HD). Compounds were identified that potentiate the lethality of anti-tumor agents as well as rescue a disease-state lethality. These compounds are acylated secondary amines referred to herein as indoxins and revertins.

  高通量筛选（HTS）方法通过小分子筛选，用于鉴定可用于治疗或预防癌症（例如使细胞克服E6致癌蛋白介导的药物耐药性的化合物）或神经退行性疾病（例如亨廷顿病，HD）的化合物。已鉴定出可增强抗肿瘤药物的致死性并挽救疾病状态致死性的化合物。这些化合物是称为indoxins和revertins的酰化次级胺。